Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045312 | 0.85 | MAPK14 (0.51) | MAP4K4EGFRERBB2MAPK14ALDH1A1 | |
| SCHEMBL277131 | 0.84 | MAP4K4 (0.61) | MAP4K4EGFRERBB2MAPK14GRM5 | |
| SCHEMBL17708304 | 0.78 | TGFBR1 (0.44) | MAP4K4EGFRERBB2GRM5CA12 | |
| SCHEMBL27122036 | 0.78 | MAP4K4 (0.50) | MAP4K4EGFRERBB2MAPK14GRM5 | |
| SCHEMBL27120716 | 0.78 | MAP4K4 (0.40) | MAP4K4EGFRERBB2MAPK14KDR | |
| SCHEMBL17365039 | 0.75 | MAP4K4 (0.47) | MAP4K4EGFRERBB2GRM5CA12 | |
| SCHEMBL12491760 | 0.74 | MAP4K4 (0.46) | MAP4K4EGFRERBB2GRM5MEN1 | |
| SCHEMBL5137204 | 0.74 | MAP4K4 (0.45) | MAP4K4EGFRERBB2GRM5ALDH1A1 | |
| SCHEMBL31133184 | 0.73 | MAP4K4 (0.49) | MAP4K4EGFRERBB2CA12CA1 | |
| SCHEMBL13408013 | 0.73 | MAP4K4 (0.52) | MAP4K4EGFRERBB2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653437-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Innovo Therapeutics Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024154979-A2 | NOVEL HETEROCYCLIC COMPOUNDS | 주식회사 이노보테라퓨틱스 | 2024-07-25 | — | — | WO | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20220135584-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | REVOLUTION MEDICINES INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135584-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | REVOLUTION MEDICINES INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-113767100-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2021-12-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | MAP4K4 2308/4885EGFR 3562/4885ERBB2 2515/4885 |
| US-20220135584-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | MAP4K4 1664/4885EGFR 1567/4885ERBB2 888/4885 |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | MAP4K4 1664/4885EGFR 1567/4885ERBB2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.